
---
title: '神济昌华科学顾问委员会成立仪式暨基因治疗论坛成功举行'
categories: 
 - 新媒体
 - MIT 科技评论
 - 首页
headimg: 'https://image.deeptechchina.com/article/2022022111161871697.png'
author: MIT 科技评论
comments: false
date: Mon, 21 Feb 2022 03:09:00 GMT
thumbnail: 'https://image.deeptechchina.com/article/2022022111161871697.png'
---

<div>   
<p style="text-align:justify;; line-height:28.0000pt; mso-line-height-rule:exactly"><font face="黑体" size="5"><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">    2022</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">年</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">2</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">月</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">18</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">日下午，一场以“神济携初心而来</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;"> </span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">昌华为梦想而生”为主题的“神经系统疾病基因治疗产业发展论坛—暨神济昌华科学顾问委员会成立仪式”在中关村生命科学园举办。中国科学院院士王以政，北京市昌平区区委常委、副区长杨仁全，</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">北医</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">三</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">院副院长兼神经科主任</span><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">樊东升，京东副总裁蔡磊，清华大学药学院教授鲁白，清华大学医学院院长、教授祁海，基础医学系主任、教授林欣，赛业（广州）生物科技有限公司董事长韩蓝青，广州派真生物技术有限公司董事长李华鹏等嘉宾应邀出席。</span></font></p><p style="text-align:justify;; line-height:28.0000pt; mso-line-height-rule:exactly"><font face="黑体" size="5"><span style="text-align: justify; text-indent: 28pt; line-height: 150%;">      </span></font><img src="https://image.deeptechchina.com/article/2022022111161871697.png" contenteditable="false" style="font-size: 14px; max-width: 100%;" referrerpolicy="no-referrer"></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 中国科学院院士 王以政</font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111061390366.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 清华大学医学院院长、教授 祁海  </font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">近年来，随着基础研究领域长足进展，全球基因治疗从研发到临床应用进入发展快车道，或将成为抗体药物之后生物医药产业重点发展方向之一。据弗若斯特沙利文（</span><span style="line-height: 150%;">Frost & Sullivan</span><span style="line-height: 150%;">）分析，预计至</span><span style="line-height: 150%;">2025</span><span style="line-height: 150%;">年，全球基因治疗市场规模将达到近</span><span style="line-height: 150%;">305.4</span><span style="line-height: 150%;">亿美元，中国将达到</span><span style="line-height: 150%;">178.9</span><span style="line-height: 150%;">亿美元</span><span style="line-height: 150%;">。</span><b><span style="line-height: 150%;"></span></b></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">神经系统疾病是全球基因治疗产业的“硬骨头”，又是基因治疗产业最重要的应用领域之一。目前针对神经系统疾病的临床药物极其有限，基本处在无药可施状态。其中，渐冻症（肌萎缩侧索硬化症，英文缩写</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">）是最为恶性的一种神经退行性疾病，迫切需要有效的治疗药物。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">论坛开始，樊东升主任从一线临床医生的角度出发，带来题为《如何将中国</span><span style="line-height: 150%;">MND/ALS</span><span style="line-height: 150%;">临床资源优势在新药研发转化中释放出来》的主旨报告。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111062389627.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 北京大学第三医院副院长兼神经科主任 樊东升</font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">他的报告提到全球</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">发病呈上升趋势，随着人口老龄化，到</span><span style="line-height: 150%;">2040</span><span style="line-height: 150%;">年全球</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">发病人数预计将增加到约37</span><span style="line-height: 150%;">.6万</span><span style="line-height: 150%;">人。我国目前</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">每年新发约</span><span style="line-height: 150%;">2.3</span><span style="line-height: 150%;">万新病人，迫切需要加快</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">临床新药试验，同时广大病患群也为新药研发的临床试验提供重要支撑。</span><span style="line-height: 150%;"></span></font></p><p style="text-align:justify;"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111063883161.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 京东副总裁 蔡磊</font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">“预计可能我与大家能够充分交流的时间只剩几个月了。”当</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">患者、京东集团副总裁蔡磊用略带沙哑的嗓音向与会者交流自己的心路历程，这句语调平静却充满紧迫感的话语让与会者深感震撼。</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">“今天我要向神济昌华的科学家点赞，他们的挺身而出为攻克ALS带来了福音。”</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111064743907.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 清华大学医学院研究员、神济昌华科学顾问委员会主席 贾怡昌</font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111065929662.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"><span style="text-indent: 24pt;">图 | </span><span style="text-indent: 24pt;">清华大学医学院教授、基础医学系主任 林欣</span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">蔡磊的报告引起与会者强烈共鸣，大家就渐冻症与罕见病展开了激烈的讨论。神济昌华重点布局</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">，其首席科学家清华大学医学院贾怡昌研究员在</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">领域默默深耕近十年，取得ALS新靶点的重大突破。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><span style="line-height: 150%;"><font face="黑体" size="5">在论坛环节，与会专家围绕“如何看待高校基础科研转化”“神经系统疾病基因治疗的未来”“动物模型在神经系统疾病治疗中的应用”及“动员全社会的力量攻克渐冻症”等四大主题展开了深入交流和讨论。</font></span></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111071162472.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="text-indent: 24pt;">图 | </span><span style="text-indent: 24pt;">论坛环节：鲁白（线上）、林欣、祁海、王玉柱、王飙、王俊峰</span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">作为科学家创业的代表，鲁白和林欣教授均认为高校科学家的优势在于，在一个细分领域深耕多年，往往能获得突破性的原创成果。而成果转化需要组建科学家、商业运作和企业管理人才并重的人才团队，推动创新成果转化。在此过程中，基础科研和产业转化又可以相互促进，协同发展。清华大学技术转移院院长助理王玉柱表示清华正在不断完善和鼓励基础科研向产业转化的制度与体系，神济昌华是其中一个典型代表。华控技术转移有限公司（“华控”）总经理王飙在交流中表示，作为清华大学资产管理有限公司全资子公司，华控会代表学校全力支持和服务好清华大学创新成果的产业化。</span><span style="line-height: 150%; background: rgb(0, 255, 0);"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">与会专家在“神经系统疾病基因治疗的未来”“动物模型在神经系统疾病治疗中的应用”讨论中，普遍认为神经系统疾病未来将为基因治疗最重要的应用领域之一。而神济昌华拥有自主知识产权的ALS动物模型和动物模型构建上的超前理念，以及在AAV神经系统递送开发的专业精神将助力基因治疗在神经系统疾病中的应用。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; line-height:150%; text-align:justify;"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-align:justify;"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111072223291.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 论坛环节：郭亮、林欣、王以政、祁海、李华鹏、韩蓝青</font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111073265201.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"><span style="text-indent: 24pt;">图 | </span><span style="text-indent: 24pt;">论坛环节：张雪、贾怡昌、王以政、樊东升、韩蓝青、郭炜</span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5"></font></p><p style="text-indent:28.0000pt; text-align:justify;"><font face="黑体" size="5">之后，王以政院士、樊东升副院长、京东副总裁蔡磊、生命园公司董事长王颖、清华大学医学院贾怡昌共同见证神济昌华与派真生物签署了“共同开发靶向神经系统新型AAV衣壳”的协议。</font></p><p style="text-indent:28.0000pt; text-align:justify;"><img src="https://image.deeptechchina.com/article/2022022111074248290.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:28.0000pt; text-align:justify;"><font face="黑体" size="5"><span style="text-indent: 24pt;">图 | </span><span style="text-indent: 24pt;">神济昌华与派真生物签约</span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; mso-pagination:none; text-align:justify;; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; mso-pagination:none; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">另外，</span><span style="line-height: 150%;">神济昌华与赛业（苏州）生物科技有限公司（“赛业生物”）签署了“神经退行性疾病及罕见病模式动物开发”的合作协议；与赛业（广州）生物科技有限公司（以下简称“广州赛业</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">”）签署了“</span><span style="line-height: 150%;">ASO</span><span style="line-height: 150%;">核酸药物开发”的合作协议，共同为神经退行性疾病及罕见病动物模型开发和小核酸药物在神经系统疾病和罕见病的应用助力。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; mso-pagination:none; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><span style="line-height: 150%;"><img src="https://image.deeptechchina.com/article/2022022111075644047.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></span></p><p style="text-align:justify;; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 神济昌华与赛业生物、广州赛业签约<span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">为加速推动神济昌华在神经系统疾病基因治疗的进展，众多嘉宾见证了神济昌华科学顾问委员会成立。王以政院士、蔡磊、樊东升、鲁白、李路明、祁海、林欣、李华鹏、韩蓝青、徐富强（中科院精密测量科学与技术创新研究院</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">研究员）、徐文联（深圳国利健医药科技有限公司</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">总经理）、王俊峰（清华大学技术经济研究所</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">所长）、海棠（中科院动物所副研究员）等业界资深人士成为顾问委员会首批专家，清华大学医学院研究员、神济昌华联合创始人贾怡昌担任本届顾问委员会主席。</span><span style="line-height: 150%;"></span></font></p><p style="text-align:justify;"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111080764408.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 部分科学顾问委员会与神济昌华创始团队合影</font></p><p style="text-align:justify;"><font face="黑体" size="5"></font></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><img src="https://image.deeptechchina.com/article/2022022111081759124.png" style="max-width:100%;" contenteditable="false" referrerpolicy="no-referrer"></p><p style="text-indent:24.0000pt; mso-char-indent-count:2.0000; text-align:justify;; line-height:150%"><font face="黑体" size="5">图 | 部分科学顾问委员会与神济昌华创始团队合影<span style="line-height: 150%;"></span></font></p><p style="text-align:justify;"><font face="黑体" size="5"></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><p style="text-indent:28.1000pt; mso-char-indent-count:2.0000; line-height:150%; text-align:justify;"><b><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></b></p><p style="text-indent:28.1000pt; mso-char-indent-count:2.0000; line-height:150%; text-align:justify;"><font face="黑体" size="5"><b><span style="line-height: 150%;">延伸阅读</span></b><span style="line-height: 150%;"></span></font></p><p style="text-indent:32.1500pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><b><span style="line-height: 150%;">关于神济昌华</span></b><b><span style="line-height: 150%;"></span></b></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">神济昌华（北京）生物科技有限公司（简称</span><span style="line-height: 150%;">“</span><span style="line-height: 150%;">神济昌华</span><span style="line-height: 150%;">”</span><span style="line-height: 150%;">，英文名</span><span style="line-height: 150%;">“SineuGene”</span><span style="line-height: 150%;">）位于北京市昌平区中关村生命科学园，是从事创新药物研发为主的生物科技公司。创始团队均来自清华大学：CEO彭林为清华大学博士，原为南京天印健康公司总经理；CSO郭炜博士，原为清华大学药学院副研究员；科学委员会主席贾怡昌为清华大学医学院研究员。神济昌华致力于以基因治疗技术为手段，包括</span><span style="line-height: 150%;">AAV</span><span style="line-height: 150%;">介导的基因编辑、表达和以小核酸药物为核心实现对目标基因的干预，主要聚焦肌萎缩侧索硬化症（</span><span style="line-height: 150%;">ALS</span><span style="line-height: 150%;">）、脑卒中（</span><span style="line-height: 150%;">Stoke</span><span style="line-height: 150%;">）、帕金森病（</span><span style="line-height: 150%;">PD</span><span style="line-height: 150%;">）、阿尔兹海默症（</span><span style="line-height: 150%;">AD</span><span style="line-height: 150%;">）等神经系统疾病，尤其是神经退行性疾病，期望最终能够为人类解决这些重大的医疗健康难题。</span><span style="line-height: 150%;">2022</span><span style="line-height: 150%;">年</span><span style="line-height: 150%;">1</span><span style="line-height: 150%;">月，神济昌华完成千万级种子轮融资，为北京生命科学园创新投资基金独家投资。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:32.1500pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><b><span style="line-height: 150%;">关于派真生物</span></b><b><span style="line-height: 150%;"></span></b></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">派真生物（</span><span style="line-height: 150%;">PackGene</span><span style="line-height: 150%;">）是一家全球领先的</span><span style="line-height: 150%;">AAV</span><span style="line-height: 150%;">病毒载体包装</span><span style="line-height: 150%;">CRO</span><span style="line-height: 150%;">和</span><span style="line-height: 150%;">CDMO</span><span style="line-height: 150%;">公司</span><span style="line-height: 150%;">, </span><span style="line-height: 150%;">以质粒和</span><span style="line-height: 150%;">AAV</span><span style="line-height: 150%;">载体创新生产体系、方法学检测、以及</span><span style="line-height: 150%;">GMP</span><span style="line-height: 150%;">规模化生产为核心</span><span style="line-height: 150%;">, </span><span style="line-height: 150%;">依托持续技术创新，为细胞与基因治疗</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">（</span><span style="line-height: 150%;">CGT</span><span style="line-height: 150%;">）</span><span style="line-height: 150%;"> </span><span style="line-height: 150%;">的早期研发、临床前开发、临床试验以及药物审批提供经济、快速、规模化的质粒生产和</span><span style="line-height: 150%;">AAV</span><span style="line-height: 150%;">病毒载体生产。派真生物以做全球基因药物研发生产的合作伙伴为使命，以加速创新基因药物上市为己任，精通</span><span style="line-height: 150%;">FDA</span><span style="line-height: 150%;">、</span><span style="line-height: 150%;">NMPA</span><span style="line-height: 150%;">和</span><span style="line-height: 150%;">EMA</span><span style="line-height: 150%;">等对基因疗法制品的规范要求，通过降低基因药物大规模生产成本，助力合作伙伴让基因药物更早普惠大众。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:32.1500pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><b><span style="line-height: 150%;">关于赛业生物</span></b><b><span style="line-height: 150%;"></span></b></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">赛业生物科技赛业生物科技是美国</span><span style="line-height: 150%;">Cyagen Biosciences Inc </span><span style="line-height: 150%;">旗下的中国区子公司，专业从事生命科学前沿技术开发，成立于</span><span style="line-height: 150%;">2006</span><span style="line-height: 150%;">年</span><span style="line-height: 150%;">2</span><span style="line-height: 150%;">月。公司的科学团队均由来自芝加哥大学、</span><span style="line-height: 150%;">MIT</span><span style="line-height: 150%;">、</span><span style="line-height: 150%;">UCLA</span><span style="line-height: 150%;">及多家美国生物技术公司的全球一线科学家组成。赛业生物科技经营范围涵盖细胞生物学、分子生物学、转基因模式动物、生物纳米材料、体外诊断、药物筛选和生物信息学等生命科学领域多个分支学科，是一个集研发、生产、服务、销售于一体的综合性集团化商业、技术实体。</span><span style="line-height: 150%;"></span></font></p><p style="text-indent:32.1500pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><b><span style="line-height: 150%;">关于广州赛业</span></b><b><span style="line-height: 150%;"></span></b></font></p><p style="text-indent:28.0000pt; mso-char-indent-count:2.0000; text-align:justify;; text-justify:inter-ideograph; line-height:150%"><font face="黑体" size="5"><span style="line-height: 150%;">广州赛业于</span><span style="line-height: 150%;">2006</span><span style="line-height: 150%;">年在广州市开发区注册成立，历经十多年发展，已成为细胞生物学领域的知名企业。赛业旗下品牌</span><span style="line-height: 150%;">OriCell®</span><span style="line-height: 150%;">专注于细胞生物学产品研究和开发，主营业务包括细胞产品、细胞培养试剂、进口胎牛血清和细胞生物学技术服务等。</span><span style="line-height: 150%;">OriCell®</span><span style="line-height: 150%;">一直致力于为全球高等院校、研究机构、医院、</span><span style="line-height: 150%;">CRO</span><span style="line-height: 150%;">及</span><span style="line-height: 150%;">CMO</span><span style="line-height: 150%;">企业提供细胞生物学完整解决方案，产品畅销全球几十个国家与地区，引用</span><span style="line-height: 150%;">OriCell®</span><span style="line-height: 150%;">产品和服务的文献超数千篇。</span><span style="line-height: 150%;"></span></font></p><p style="line-height:150%; text-align:justify;"><font face="黑体" size="5"><span style="line-height: 150%;"></span></font></p><font face="黑体" style="text-align:justify;"><span style="font-size: 17px;">参考：</span></font><div style="text-align:justify;"><font face="黑体"><span style="font-size: 17px;">1、</span></font><span style="color: rgb(64, 64, 64); font-family: Arial, "Hiragino Sans GB", STHeiti, "Helvetica Neue", Helvetica, "Microsoft Yahei", "WenQuanYi Micro Hei", sans-serif; font-size: 18px; text-align: justify;">1、数据来自健康界，《基因治疗市场爆发，2025年市场规模将超300亿美元》https://www.cn-healthcare.com/articlewm/20210616/content-1232241.html</span></div>  
</div>
            